Novel Insights into Glioma Immunotherapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 5 November 2026 | Viewed by 5
Special Issue Editor
2. Maria Sklodowska-Curie Medical Academy, Warsaw, Poland
Interests: neurosurgery; neuro-oncology; glioma immunobiology; immunotherapy; advanced neuroimaging; translational oncology
Special Issue Information
Dear Colleagues,
Gliomas remain among the most therapeutically challenging central nervous system tumors, in large part due to their profound immunosuppressive microenvironment and remarkable biological heterogeneity. Rapid advances in tumor immunology have generated renewed interest in understanding how gliomas interact with and evade the host immune system. This Special Issue aims to consolidate emerging evidence on the cellular and molecular mechanisms governing immune resistance, including microglial and myeloid dysregulation, disrupted antigen presentation, and T-cell exhaustion. We particularly welcome studies that introduce innovative immunotherapeutic strategies—such as neoantigen-based vaccines, adoptive cellular therapies, engineered immune checkpoint modulation, and rational combination approaches integrating radiotherapy or targeted agents. Contributions that bridge preclinical discovery with translational or early clinical data are strongly encouraged, as these efforts are essential for developing precise, mechanism-driven interventions. By assembling these insights, this Special Issue seeks to advance the scientific foundation for next-generation glioma immunotherapy.
This Special Issue welcomes reviews as well as original research articles, which should be submitted by 5 November 2026.
Dr. Tomasz Tykocki
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- glioma immunotherapy
- tumor microenvironment
- immune evasion
- microglia
- checkpoint inhibitors
- CAR‑T
- neoantigen vaccines
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
